Talphera (NASDAQ:TLPH) Insider Purchases $28,350.00 in Stock

Talphera, Inc. (NASDAQ:TLPH) insider Badri Dasu purchased 35,000 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were purchased at an average cost of $0.81 per share, for a total transaction of $28,350.00. Following the transaction, the insider owned 76,230 shares of the company’s stock, valued at $61,746.30. This trade represents a 84.89% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Talphera Trading Down 3.9%

TLPH stock opened at $0.78 on Monday. The company has a market capitalization of $36.20 million, a P/E ratio of -2.04 and a beta of 0.46. The business has a 50 day simple moving average of $1.00 and a 200-day simple moving average of $0.99. Talphera, Inc. has a twelve month low of $0.38 and a twelve month high of $1.57.

Hedge Funds Weigh In On Talphera

A number of large investors have recently bought and sold shares of the company. AIGH Capital Management LLC acquired a new stake in shares of Talphera in the 3rd quarter worth $3,979,000. Rosalind Advisors Inc. raised its holdings in Talphera by 118.9% during the third quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock worth $3,917,000 after purchasing an additional 2,381,818 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in Talphera by 75.3% during the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after purchasing an additional 1,500,000 shares in the last quarter. Empery Asset Management LP acquired a new stake in Talphera in the fourth quarter valued at about $1,520,000. Finally, Cantor Fitzgerald L. P. purchased a new stake in Talphera in the 4th quarter valued at approximately $658,000. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on TLPH shares. Wall Street Zen upgraded shares of Talphera to a “hold” rating in a research note on Saturday, November 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.